Foley Partner Brett Ludwig will be presenting in a session called “Anticipating Reinsurance Disputes: Contract Wordings That Facilitate Resolutions” on Tuesday, April 29, 2008 during the American Conference Institute’s Reinsurance Agreements: New Approaches for Ensuring Comprehensive and Secure Business Arrangements in a Changing Environment conference at the Flatotel Hotel in New York City.
Brett will be joined by Peter Szendro, Senior Vice President & Reinsurance Counsel of Willis Re Inc.; James Veach, Partner at Mound Cotton Wollan & Greengrass; and Kevin Helewa, Vice President and Associate General Counsel of Everest Reinsurance Company. The presentation will focus on:
- How and when to use tiered arbitration wordings to allow for litigation
- Addressing disclosure and evidentiary matters in arbitration agreements
- Determining the qualification requirements and selection process for arbitration panel members
- Providing for consolidated proceedings
- Confirming or objecting to final awards
- How the arbitration agreement relates to other contract provisions:
- Errors and omissions
- Access to records
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.